Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
137.75
+8.65 (6.70%)
At close: Feb 21, 2025, 4:00 PM
138.95
+1.20 (0.87%)
After-hours: Feb 21, 2025, 6:21 PM EST
Axsome Therapeutics Employees
Axsome Therapeutics had 545 employees as of December 31, 2023. The number of employees increased by 162 or 42.30% compared to the previous year.
Employees
545
Change (1Y)
162
Growth (1Y)
42.30%
Revenue / Employee
$707,694
Profits / Employee
-$527,002
Market Cap
6.72B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
AXSM News
- 2 days ago - Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering - Seeking Alpha
- 4 days ago - Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade - Seeking Alpha
- 12 days ago - Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' - Benzinga
- 22 days ago - Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader - GlobeNewsWire
- 22 days ago - US FDA approves Axsome Therapeutics' migraine drug - Reuters
- 23 days ago - Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults - GlobeNewsWire
- 7 weeks ago - Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results - Seeking Alpha